BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38911369)

  • 1. Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma.
    Ye Z; Wang Y; Yuan R; Ding R; Hou Y; Qian L; Zhang S
    J Cancer; 2024; 15(12):3645-3662. PubMed ID: 38911369
    [No Abstract]   [Full Text] [Related]  

  • 2. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
    Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
    Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constructing and validating of m7G-related genes prognostic signature for hepatocellular carcinoma and immune infiltration: potential biomarkers for predicting the overall survival.
    Liu P; Dong C; Shi H; Yan Z; Zhang J; Liu J
    J Gastrointest Oncol; 2022 Dec; 13(6):3169-3182. PubMed ID: 36636051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
    Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
    Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of
    Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
    Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a breast cancer prognostic model based on vesicle-mediated transport-related genes to predict immune landscape and clinical drug therapy.
    Zhu X; Wang F; Wang M; Lv L; Fang L; Song J; Wang X; Ding F
    Hum Mol Genet; 2024 Mar; 33(7):553-562. PubMed ID: 38129105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of subtypes of hepatocellular carcinoma and screening of prognostic molecular diagnostic markers based on cell adhesion molecule related genes.
    Sun R; Gao Y; Shen F
    Front Genet; 2022; 13():1042540. PubMed ID: 36482887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic exosome-related long non-coding RNAs risk model related to the immune microenvironment and therapeutic responses for patients with liver hepatocellular carcinoma.
    Yue Y; Tao J; An D; Shi L
    Heliyon; 2024 Jan; 10(2):e24462. PubMed ID: 38293480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a Cancer Stem Cell related Histone Acetylation Regulatory Genes Prognostic Model for Hepatocellular Carcinoma via Bioinformatics Analysis: Implications for Tumor Chemotherapy and Immunity.
    Dai Q; Zhu J; Yang J; Zhang CY; Yang WJ; Pan BS; Yang XR; Guo W; Wang BL
    Curr Stem Cell Res Ther; 2024 Mar; ():. PubMed ID: 38561604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
    Wang L; Wang Q; Li Y; Qi X; Fan X
    J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a vesicle-mediated transport-associated gene signature for predicting prognosis and immune therapy response in hepatocellular carcinoma.
    Liu ZY; Li YH; Li BW; Xin L
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13211-13230. PubMed ID: 37479759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Pyroptosis-Related Prognostic Signature Combined With Experiments in Hepatocellular Carcinoma.
    Li H; Li T; Zhang X
    Front Mol Biosci; 2022; 9():822503. PubMed ID: 35309514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.